Technical Series on Safer Primary Care
Examination of the business behavior of Boehringer Ingelheim, Bayer and Baxter in India
Guidelines
UNAIDS/WHO working group on global HIV/AIDS and STI surveillance
August 2015
HIV strategic information for impact
Progress report of the Human Rights Council Advisory Committee (A/HRC/33/53) (Advance edited version)
This is the second guidance note in a four-part series of notes related to impact evaluation developed by InterAction with financial support from the Rockefeller Foundation.This second guidance note, Linking Monitoring and Evaluation to Impact Evaluation, illustrates the relationship between routine... M&E and impact evaluation – in particular, how both monitoring and evaluation activities can support meaningful and valid impact evaluation. The guidance note is also available in French, Arabic and Spanish on https://www.interaction.org/impact-evaluation-notes.
more
July 2018
This fourth edition of the Unitaid/WHO market and technology landscape: HIV rapid diagnostic tests for self-testing report summarizes the current HIV testing gap; the challenges facing efforts to scale up; and the potential role HIV self-testing (HIVST) could play to achieve the United... Nation’s 90-90-90 targets. In particular, the report synthesises the existing and emerging market demand and supply of kits.
The information in this report is intended for manufacturers, donors, national programmes, researchers and other global health stakeholders who are exploring the potential role of HIVST.
more
Following review of the latest evidence, WHO recommends that TB-LAMP can be used as a replacement for microscopy for the diagnosis of pulmonary TB in adults with signs and symptoms of TB. It can also be considered as a follow-on test to microscopy in adults with signs and symptoms of pulmonary TB, e...specially when further testing of sputum smear-negative specimens is necessary.
more
The goal of the draft global action plan is to ensure, for as long as possible, continuity of successful treatment and prevention of infectious diseases with effective and safe medicines that are quality-assured, used in a responsible way, and accessible to all who need them.
There is an urgent need for safer, simpler, more efficacious and accessible treatment regimens for all forms of TB. The development of Target Product Profiles for TB treatment regimens (referred to as Target Regimen Profiles or TRPs) seeks to guide the drug development process towards important regi...men characteristics corresponding to the needs of end-users.
more
This EISF report provides an analysis of the issues surrounding the relationship between NGO’s and their local partners. It includes a section on the topic and its background, responsabilities towards the partner organisation and particularly in terms of security, how to enable and help the partne...r in developing a project from start to finish, the challenges of developing that capacity in the partner organisation. It also includes three anexes, namely a Partner Security Level Assessment, a Checklist of organisational security perspectives and Participants.
more